How is it Processed?

GRAFTJACKET Regenerative Tissue Matrix

regeneration tissue

The patented cryogenic processing of the GRAFTJACKET Matrix prevents ice crystal formation thus minimizing any damage to the matrix to help avoid an inflammatory response to the graft.

By protecting the matrix through the processing steps, the vascular channels are preserved as demonstrated in this electron micrograph.

Dermis is very vascular making the GRAFTJACKET Matrix an excellent graft template for many different tissue type repairs.

These channels act as a template for rapid initial revascularization through what is called inosculation. This is simply communication of existing blood vessels in the body with the preserved channels in the graft. New blood vessels will be formed later through the process known as angiogenesis.

regeneration tissue

What makes the GRAFTJACKET Matrix unique is the processing.

Proper processing is very important to allow for tissue regeneration via a like-for-like tissue scaffold.

The first step in the processing is to remove the cellular components, or antigens from the human tissue. This helps to minimize any rejection response to the allograft.

In removing the cellular components, you keep in place the collagen, elastin, and proteoglycan components, important components of the extracellular matrix, which allows for rapid revascularization and cellular repopulation.

It is also very important that you preserve the intact matrix. This minimizes any damage to the matrix, avoids any artificial crosslinking and as a result minimizes inflammatory response.

Processing is key – you can begin with the same material, but if it’s put through a different process, it will result in a very different material that could behave very differently in the body.

The GRAFTJACKET Matrix material has been demonstrated to show the regeneration of normal and functional host tissue.

graftjacket_int_04

The GRAFTJACKET Matrix technology has a long history of clinical efficacy in multiple sub-specialties with more than 12 years on the market.

Greater than 1 million implants of the technology demonstrating a strong safety record.

The product allows for rapid revascularization, ultimately minimizing the risk of infection.